AGÕæÈ˹ٷ½

STOCK TITAN

[8-K] Septerna, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
false 0001984086 0001984086 2025-07-30 2025-07-30
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 30, 2025

 

 

Septerna, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-42382   84-3891440

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

250 East Grand Avenue  
South San Francisco, California   94080
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: 650 338-3533

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   SEPN   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 
 


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 30, 2025, the Board of Directors (the “Board”) of Septerna, Inc. (the “Company”) appointed Liz Bhatt, M.S., M.B.A., the Company’s Chief Operating Officer, to serve as the Company’s President, in addition to continuing in her current role as Chief Operating Officer, effective as of August 1, 2025 (the “Effective Date”). Ms. Bhatt will assume the title of President from Jeffrey Finer, M.D., Ph.D, who will continue to serve as the Company’s Chief Executive Officer and principal executive officer from the Effective Date.

Ms. Bhatt has served as the Company’s Chief Operating Officer since June 2022. Her biography is set forth in the Company’s definitive proxy statement for its 2025 annual meeting of stockholders filed with the Securities and Exchange Commission pursuant to Regulation 14A on April 29, 2025.

There are no arrangements or understandings between Ms. Bhatt and any other persons pursuant to which she was selected as President, and there are no family relationships between Ms. Bhatt and any of the Company’s directors or executive officers. There are no transactions to which the Company is a party and in which Ms. Bhatt has a direct or indirect material interest that would be required to be disclosed under Item 404(a) of Regulation S-K.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      Septerna, Inc.
Date: August 4, 2025     By:  

/s/ Jeffrey Finer, M.D., Ph.D.

     

Jeffrey Finer, M.D., Ph.D.

Chief Executive Officer

Septerna, Inc.

NASDAQ:SEPN

SEPN Rankings

SEPN Latest News

SEPN Latest SEC Filings

SEPN Stock Data

523.56M
43.38M
2.64%
105.6%
8.4%
Biotechnology
Pharmaceutical Preparations
United States
SOUTH SAN FRANCISCO